Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical
MWN-AI** Summary
Boston Legacy FC has announced a multi-year partnership with Collegium Pharmaceutical, marking a significant step towards making its home games more inclusive for all fans. This partnership, revealed on February 23, 2026, designates Collegium as an Official Partner of the soccer club, which will debut as the 15th team in the National Women's Soccer League (NWSL) that same year.
Central to this collaboration is the establishment of the Collegium Sensory Room, which will feature at Gillette Stadium and Centreville Bank Stadium in 2026, and at White Stadium starting in 2027. The Sensory Room is designed to provide a quieter, secure environment for attendees who experience sensory sensitivities, allowing them to take breaks from the high energy of matchday experiences. The room will be equipped to support comfort and regulation, aligning with Boston Legacy FC's commitment to inclusivity.
Jennifer van Dijk, Team President, emphasized the team's vision of creating a welcoming stadium atmosphere that caters to diverse fan experiences. Vikram Karnani, President and CEO of Collegium, highlighted the partnership's mission to support individuals with neurodivergence by making community events more accessible and by promoting awareness of conditions like ADHD.
The creation of the sensory room is informed by input from leading organizations such as Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), and aims to eliminate barriers faced by individuals who may feel overwhelmed in traditional event settings.
In addition to sensory space provisions, the partnership includes branded signage and digital mentions to promote awareness of the new resources. The overall goal is to foster a supportive environment for fans and families, allowing everyone to enjoy the excitement of attending a live soccer match.
MWN-AI** Analysis
The recent announcement of Boston Legacy FC's partnership with Collegium Pharmaceutical to create sensory rooms at their home matches represents a significant shift in the sporting landscape, focusing on inclusivity and community engagement. This collaboration not only positions Boston Legacy FC as a forward-thinking organization in the National Women’s Soccer League (NWSL) but also places Collegium at the forefront of social responsibility in health care.
From a market perspective, Boston Legacy FC's commitment to providing sensory-inclusive environments can attract a broader audience, including families and individuals with neurodevelopmental conditions such as ADHD and autism. This strategic decision enhances fan engagement and loyalty, translating into potential increases in game attendance and merchandise sales. Clubs that prioritize inclusivity often see positive responses from local communities, which can bolster brand reputation and loyalty, key factors in an era where fan experience is paramount.
Moreover, Collegium Pharmaceutical’s involvement in this initiative underscores its mission to connect with the community and enhance the lives of individuals with serious medical conditions. As a growing player in the biopharmaceutical space, their visibility in a community-focused partnership could lead to heightened brand recognition and potential growth in their ADHD portfolio—a market that is gaining notable attention.
Investors should monitor both Boston Legacy FC and Collegium Pharmaceutical closely, as this partnership could yield significant wins for both organizations. For Boston Legacy FC, sustained fan engagement can enhance revenue streams, while for Collegium, increased brand awareness in the community may drive consumer interest in their products.
Overall, this partnership reflects positively on both entities, promising increased community involvement while setting a precedent for future collaborations that bridge sports and social responsibility. Investing in companies that advocate for inclusivity can often yield sustainable growth and foster a sense of community, making such partnerships worth watching.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are working together to ensure that the club’s home games are welcoming and sensory-inclusive for all fans.
As part of the partnership, the Collegium Sensory Room will be available at Gillette Stadium and Centreville Bank Stadium in 2026, and White Stadium beginning in 2027, for all Boston Legacy FC home matches. The dedicated space will provide a quieter, more secure environment for guests who may need a break from the visual and auditory stimulation of a matchday experience. The room will be outfitted to support comfort and regulation, helping ensure a positive and inclusive guest experience for all fans.
“We want every fan to feel like Boston Legacy FC is truly their club,” said Jennifer van Dijk, Team President of Boston Legacy FC. “That means delivering an unforgettable, high-energy matchday experience while also being thoughtful about how people experience sound, light, and crowd environments. We’re reimagining how a stadium can function and feel, with the goal of being as accommodating and welcoming as possible to every individual. Through our partnership with Collegium, we’re proud to create a space where fans and families feel comfortable and supported.”
“Collegium’s partnership with Boston Legacy FC reflects what we value most: showing up for our community and helping people with neurodivergence feel seen, supported, and included,” said Vikram Karnani, President and Chief Executive Officer of Collegium. “Initiatives like this are tangible steps toward making community events, like game days, accessible and inclusive for more fans and raising awareness and understanding of neurodevelopmental disorders, such as ADHD.”
Sensory sensitivities or challenges with sensory regulation are commonly experienced by individuals with ADHD, autism, dementia, PTSD, and other conditions. Large-scale sporting events can present barriers for these individuals due to heightened noise levels, crowds, and visual stimulation. The Collegium Sensory Room is designed to help remove those barriers and make matchday accessible to more fans and families.
The sensory rooms are being designed with input from Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), the nation’s leading nonprofit organization serving people affected by ADHD.
“For some fans and families, a sensory room is the difference between ‘we can’t do this’ and ‘we can.’ For many of us with ADHD, large venues, big crowds, and noise can be overwhelming — not because we don’t want to be there, but because our nervous systems process stimulation differently,” Suzanne Sophos, President, CHADD. “A sensory room provides a place to reset before overwhelm turns into dysregulation, which can help people stay longer and enjoy the event. That kind of access, and that kind of being seen, is a game changer.”
The partnership includes branded signage within the Sensory Room and mentions across Boston Legacy FC’s digital platforms, including “Know Before You Go” communications and fan resource information. The partnership will also support inclusive community programming for youth and caregivers.
About Boston Legacy FC
Boston Legacy FC will add to Boston’s winning legacy as the 15th team in the National Women’s Soccer League (NWSL) starting play in 2026. Founded and led by women, the club is committed to creating a home for the greatest female athletes of our time, building upon the supercharged legacy of Boston’s historic sports teams, cultivating a community of fans with impact at its core, and forging new connections across our city through sport. For more information, please visit bostonlegacyfc.com or its social media platforms – LinkedIn, Instagram, Twitter (X), TikTok, Bluesky, Facebook
About Collegium Pharmaceutical
Collegium is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business. Collegium’s strategy includes growing its commercial portfolio, with ADHD as the lead growth driver, and deploying capital in a disciplined manner. Collegium is also a proud sponsor of CHADD. For more information, please visit www.collegiumpharma.com and follow @CollegiumPharma on X and LinkedIn.
Media Contact
Sara Rooke
Director of Communications, Boston Legacy FC
srooke@bostonlegacyfc.com
617-872-9453
For Collegium Inquiries:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f2e5272a-d05a-460c-b6b9-141269695c66
https://www.globenewswire.com/NewsRoom/AttachmentNg/f5cf71c9-9c3c-48c7-8701-d35237de8dd2
FAQ**
How does the partnership between Boston Legacy FC and Collegium Pharmaceutical Inc. COLL enhance the matchday experience for fans with sensory sensitivities?
What specific features will the Collegium Sensory Room include to support fans with neurodivergence at Boston Legacy FC games?
In what ways does Collegium Pharmaceutical Inc. COLL plan to engage with the community through this partnership with Boston Legacy FC?
How will Collegium Pharmaceutical Inc. COLL’s focus on ADHD within its portfolio align with the initiatives supported through the Boston Legacy FC partnership?
**MWN-AI FAQ is based on asking OpenAI questions about Collegium Pharmaceutical Inc. (NASDAQ: COLL).
NASDAQ: COLL
COLL Trading
0.03% G/L:
$37.21 Last:
82,716 Volume:
$37.24 Open:
